TrialA Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
Trial details
- Registry ID
- NCT05856760
- Phase
- Phase 2
Drug research
Sparsentan
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Filspari; RE-021
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgANNCT05856760 | TVTX | Phase 2 | Completed | 2024-10-14Actual |
| Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesNCT05003986 | TVTX | Phase 2 | Recruiting | 2027-03-12Estimated |
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
Trial details
- Registry ID
- NCT05003986
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |